GVAG
BLRX

Great Valley Advisor Group’s BioLineRX BLRX Stock Holding History

Great Valley Advisor Group’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-308
Closed -$20K – 682
2023
Q2 		$20K Buy
+308
New +$17.1K ﹤0.01% 692

Other funds holding BLRX

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
VFA
Values First Advisors Gray, Tennessee $192M AUM 24.96% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return

Great Valley Advisor Group's BLRX Position: Q3 2023 in Review

Great Valley Advisor Group sold out of BioLineRX (BLRX) in Q3 2023, closing a stake of 308 shares — an estimated $20K sold.

Great Valley Advisor Group first reported a position in BLRX in Q2 2023 and held it in 1 quarter. The position peaked at $20K in Q2 2023. 29 funds tracked by Wall St. Rank hold BLRX as of Q3 2023.

  • Great Valley Advisor Group reported no remaining BioLineRX position as of Q3 2023 after selling out during the quarter.
  • Great Valley Advisor Group sold 308 BioLineRX shares in Q3 2023, an estimated $20K.
  • Great Valley Advisor Group first reported a position in BioLineRX in Q2 2023 and held it in 1 quarter.
  • Great Valley Advisor Group's BioLineRX position peaked at $20K in Q2 2023.
  • 29 funds tracked by Wall St. Rank held BioLineRX as of Q3 2023.

Based on Great Valley Advisor Group's 13F filing for Q3 2023, filed 7 Nov 2023.